Previous 10 | Next 10 |
Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1 Canada NewsWire HAMILTON, ON and BOSTON , June 23, 2022 /CNW/ -- Fusion Pharmaceuti...
Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434 Canada NewsWire - Study evaluates pre-administration of cold antibody prior to administration of imaging agent - Imaging shows favorable gain in tumor les...
Clinical-stage oncology company Fusion Pharmaceuticals (NASDAQ:FUSN) and Niowave, a maker of medical radioisotopes, on Friday said that they have entered into a collaboration for the development, production, and supply of actinium-225. Actinium-225, an isotope of the element actinium, emits h...
Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement Canada NewsWire Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of ...
Fusion Pharmaceuticals (NASDAQ:FUSN) is trading lower in the morning hours Thursday after the clinical-stage oncology company pushed back key milestones related to its early-stage studies for cancer candidates FPI-1434 and FPI-1966. The company revised the timeline to report Phase 1 data for ...
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs Canada NewsWire HAMILTON, ON and BOSTON , June 9, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next...
Fusion Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference Canada NewsWire HAMILTON , ON and BOSTON , June 6, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on develo...
Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day Canada NewsWire HAMILTON , ON and BOSTON , May 11, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on dev...
Fusion Pharmaceuticals press release (NASDAQ:FUSN): Q1 GAAP EPS of -$0.46. Revenue of $0.59M. As of March 31, 2022, Fusion held cash, cash equivalents and investments of $206.7 million, compared to cash, cash equivalents and investments of $220.8 million as of December 31, 2021. For further...
Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates Canada NewsWire Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and adva...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...